Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 29:2019:5324170.
doi: 10.1155/2019/5324170. eCollection 2019.

Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis

Rebecca S Y Wong  1
Affiliations
Review

Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis

Rebecca S Y Wong. Adv Pharmacol Sci. .

Abstract

Spondyloarthritis or spondyloarthropathy (SpA) is a group of related rheumatic disorders, which presents with axial and nonaxial features, affecting structures within the musculoskeletal system, as well as other bodily systems. Both pharmacological and nonpharmacological therapeutic options are available for SpA. For decades, nonsteroidal anti-inflammatory drugs (NSAIDs) have been used as the first-line drugs to treat the disease. Research has shown that other than pain relief, NSAIDs have disease-modifying effects in SpA. However, to achieve these effects, continuous and/or long-term NSAID use is usually required. This review will give an overview of SpA, discuss NSAIDs and their disease-modifying effects in SpA, and highlight some of the important adverse effects of long-term and continuous NSAID use, particularly those related to the gastrointestinal, renal, and cardiovascular systems.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Prati C., Claudepierre P., Pham T., Wendling D. Mortality in spondylarthritis. Joint Bone Spine. 2011;78(5):466–470. doi: 10.1016/j.jbspin.2011.02.012. - DOI - PubMed
    1. van der Heijde D., Ramiro S., Landewé R., et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases. 2017;76(6):978–991. doi: 10.1136/annrheumdis-2016-210770. - DOI - PubMed
    1. Caso F., Costa L., Del Puente A., et al. Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies. Therapeutic Advances in Chronic Disease. 2015;6(6):328–338. doi: 10.1177/2040622315608647. - DOI - PMC - PubMed
    1. Haibel H., Fendler C., Listing J. Efficacy of oral prednisolone in active ankylosing spondylitis–results of a double blind placebo controlled trial. Annals of the Rheumatic Diseases. 2012;71(3):p. 247. - PubMed
    1. Wendling D., Lukas C., Paccou J., et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2014;81(1):6–15. doi: 10.1016/j.jbspin.2013.12.002. - DOI - PubMed

LinkOut - more resources